Two Class 1 new drugs have also been approved for new indications: Luconshatuo Monoclonal Antibody Injectable Drug (TROP2 ADC) and Tagorimab Injectable Drug (PD-L1 monoclonal antibody).
At Hong Kong Deng Yue Medicine, we regard these achievements — particularly the progress in injectable drugs and other new approvals — as valuable references that deepen our professional insight, strengthen our service capabilities, and enable us to stay ahead of industry trends, ultimately supporting patients and partners with more timely and effective solutions.